Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them.
Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown
Scientists from Mount Sinai have recently found potentially serious side effects related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma.